Understanding treatments and outcomes in patients with primary cutaneous lymphoma
Official title: Treatments and Outcomes in Patients With Primary Cutaneous Lymphoma: a Nationwide Multi-center Prospective Study in China
Run by Peking University First Hospital · NCT05518851 · Data updated 2026-11-12
This study is trying to find out how well different treatments work for people with primary cutaneous lymphoma in China to help improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Peking University First Hospital Academic / other |
| Locations | 5 sites (Beijing, Beijing Municipality and 4 other locations) |
| Status | Recruiting |
| Started | August 1, 2022 |
| Main results expected | August 2032 |
| Study ends | August 2032 |
| Registry record updated | November 18, 2023 |
| Trial ID | NCT05518851 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with a confirmed pathological diagnosis of primary cutaneous lymphoma from participating medical centers.
✕Probably not a fit
Patients who are unable to provide informed consent or cannot complete the required questionnaires may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to improve the diagnosis and treatment of primary cutaneous lymphoma (PCL) in China by establishing a standardized center for PCL. It will systematically assess the current treatment status and outcomes of patients diagnosed with PCL, which includes various types of cutaneous T-cell and B-cell lymphomas. The study will gather data from multiple medical centers to evaluate the efficacy and safety of different treatment methods, addressing the limited data available for Chinese patients with PCL.
Why it matters
Potential benefit: If successful, this study could enhance treatment strategies and improve patient outcomes for those with primary cutaneous lymphoma.
How similar studies have gone: While there have been studies on primary cutaneous lymphoma, this nationwide multi-center approach focusing on Chinese patients is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients from the participatin medical centers that has passed the data review of the National Clinical Center for Skin and Immune Diseases. * Patients with a definitive pathological diagnosis of primary cutaneous lymphoma by skin biopsy. Exclusion Criteria: * Patients who fail to provide informed consent form. * Patients who cannot complete the questionnaire independently or under the guidance of investigators.
Where it's running
-
Peking University Third Hospital
Beijing, Beijing Municipality, China Recruiting -
SUN YAI-SEN Memorial Hospital, SUN YAI-SEN University
Guandong, Guangdong, China Recruiting -
Hospital for Skin Disease, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College
Nanjing, Jiangsu, China Recruiting -
Qilu Hospital of Shandong University
Jinan, Shandong, China Recruiting -
Peking University First Hospital
Beijing, China Recruiting
Study contacts
- Principal investigator: Yang Wang, MD — Peking University First Hospital
- Study coordinator: Yang Wang, MD
- Email: yangwang_dr@bjmu.edu.cn
- Phone: (86)-10-83572350
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma
This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.
-
Q702 to treat blood cancers
This Phase 1 trial will test whether the oral drug Q702 is safe, tolerable, and what dose works best for adults with certain blood cancers who have failed or are not eligible for standard treatments.
-
Treatment for erythrodermic cutaneous T cell lymphoma using photopheresis and mogamulizumab
This study is testing a new treatment combining light therapy and a medication for people with a rare skin cancer called erythrodermic cutaneous T cell lymphoma to see if it helps them feel better and improves their quality of life.
-
Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas
This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.
-
Registry for individuals with T-cell lymphoma
This study is gathering information from people with T-cell lymphoma to help researchers learn more about the disease and improve treatments.
-
Using natural killer cells and mogamulizumab to treat relapsed or refractory cutaneous T-cell lymphomas and adult T-cell leukemia/lymphoma
This study is testing a new treatment using natural killer cells and mogamulizumab to see if it helps people with tough-to-treat skin lymphomas and adult T-cell leukemia feel better and live longer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.